Molecular profiling in Italian patients with advanced non-small-cell lung cancer: An observational prospective study.
暂无分享,去创建一个
A. Rossi | G. Rossi | A. Ceribelli | D. Galetta | S. Novello | P. Graziano | M. Tiseo | E. Maiello | A. Delmonte | M. Di Maio | E. Bria | D. Cortinovis | T. Franchina | S. Pisconti | V. Gregorc | E. Gobbini | V. Scotti | F. Riccardi | L. Buffoni | M. Migliorino | A. Catino | F. Arizio | P. Bordi | M. R. Migliorino
[1] F. Hirsch,et al. New and emerging targeted treatments in advanced non-small-cell lung cancer , 2016, The Lancet.
[2] Jean Mosser,et al. Routine molecular profiling of patients with advanced non-small-cell lung cancer: results of a 1-year nationwide programme of the French Cooperative Thoracic Intergroup (IFCT) , 2016, The Lancet.
[3] M. Socinski,et al. Alectinib in ALK-positive, crizotinib-resistant, non-small-cell lung cancer: a single-group, multicentre, phase 2 trial. , 2016, The Lancet. Oncology.
[4] J. Blay,et al. Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations. , 2015, The New England journal of medicine.
[5] G. Giaccone,et al. Targeting HER2 aberrations as actionable drivers in lung cancers: phase II trial of the pan-HER tyrosine kinase inhibitor dacomitinib in patients with HER2-mutant or amplified tumors. , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.
[6] H. Groen,et al. ASCEND-2: A single-arm, open-label, multicenter phase II study of ceritinib in adult patients (pts) with ALK-rearranged (ALK+) non-small cell lung cancer (NSCLC) previously treated with chemotherapy and crizotinib (CRZ). , 2015 .
[7] P. Jänne,et al. AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer. , 2015, The New England journal of medicine.
[8] L. Sequist,et al. Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials. , 2015, The Lancet. Oncology.
[9] F. Cappuzzo,et al. First-line crizotinib versus chemotherapy in ALK-positive lung cancer. , 2014, The New England journal of medicine.
[10] Jeffrey W. Clark,et al. Crizotinib in ROS1-rearranged non-small-cell lung cancer. , 2014, The New England journal of medicine.
[11] C. Dooms,et al. Second ESMO consensus conference on lung cancer: pathology and molecular biomarkers for non-small-cell lung cancer. , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.
[12] William Pao,et al. Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs. , 2014, JAMA.
[13] Robert Brian Jenkins,et al. Molecular Testing Guideline for Selection of Lung Cancer Patients for EGFR and ALK Tyrosine Kinase Inhibitors: Guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology , 2013, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[14] S. Peters,et al. Lung cancer that harbors an HER2 mutation: epidemiologic characteristics and therapeutic perspectives. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[15] M. Ladanyi,et al. ALK Rearrangements Are Mutually Exclusive with Mutations in EGFR or KRAS: An Analysis of 1,683 Patients with Non–Small Cell Lung Cancer , 2013, Clinical Cancer Research.
[16] C. Rudin,et al. Interim results of phase II study BRF113928 of dabrafenib in BRAF V600E mutation–positive non-small cell lung cancer (NSCLC) patients. , 2013 .
[17] J. Soria,et al. Europe does it better: molecular testing across a national health care system-the French example. , 2013, American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting.
[18] W. Travis,et al. New pathologic classification of lung cancer: relevance for clinical practice and clinical trials. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[19] J. Soria,et al. Tumour molecular profiling for deciding therapy—the French initiative , 2012, Nature Reviews Clinical Oncology.
[20] F. André,et al. Biomarker Discovery, Development, and Implementation in France: A Report from the French National Cancer Institute and Cooperative Groups , 2012, Clinical Cancer Research.
[21] E. Felip,et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. , 2012, The Lancet. Oncology.
[22] J. Abbruzzese,et al. F1000 highlights , 2009, JAMA.
[23] J. Crowley,et al. The IASLC Lung Cancer Staging Project: Proposals for the Revision of the TNM Stage Groupings in the Forthcoming (Seventh) Edition of the TNM Classification of Malignant Tumours , 2007, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[24] G. Scagliotti,et al. Phase III randomized trial comparing three platinum-based doublets in advanced non-small-cell lung cancer. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[25] M Schemper,et al. A note on quantifying follow-up in studies of failure time. , 1996, Controlled clinical trials.
[26] E. Kaplan,et al. Nonparametric Estimation from Incomplete Observations , 1958 .
[27] A. Ganti,et al. Effect of smoking on survival from non-small cell lung cancer: a retrospective Veterans’ Affairs Central Cancer Registry (VACCR) cohort analysis , 2014, Medical Oncology.